AI Analysis

Log in to generate an AI summary for this stock.

Log in to generate a MOAT report for this stock.

Log in to generate an earnings report for this stock.

Log in to generate an operating leverage report for this stock.

Log in to generate a management report for this stock.

Log in to generate a valuation report for this stock.

KALA BIO, Inc.

$0.58 -$30.48 (-98.15%)
NASDAQ · 14 Sep 2026 13:52 UTC
Previous Close
$0.57
Day Range
$0.56$0.58
Year Range
$0.49$1030
Market Cap
11.14M
AVG Volume
266.62K
Trailing/Forward PE
-0.01/-
PEG ratio
0
Dividend Yield
-
Next Earnings Date
2026-11-10
Primary Exchange
NASDAQUS
Revenue (USD) · TTM
00.250.50.75124 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
KALA Revenue (USD) · TTM by quarter
PeriodRevenue (USD) · TTM
26 Q20
26 Q10
25 Q40
25 Q30
25 Q20
25 Q10
24 Q40
24 Q30
24 Q20
24 Q10
Net Income (USD) · TTM
-40M-30M-20M-10M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
KALA Net Income (USD) · TTM by quarter
PeriodNet Income (USD) · TTM
26 Q2-10.08M
26 Q1-19.65M
25 Q4-26.98M
25 Q3-35.84M
25 Q2-37.23M
25 Q1-35.65M
24 Q4-38.51M
24 Q3-38.96M
24 Q2-38.72M
24 Q1-39.55M
Operating Income (USD) · TTM
-60M-40M-20M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
KALA Operating Income (USD) · TTM by quarter
PeriodOperating Income (USD) · TTM
26 Q2-20.99M
26 Q1-30.29M
25 Q4-39.16M
25 Q3-38.4M
25 Q2-40.72M
25 Q1-39.33M
24 Q4-40.43M
24 Q3-40.32M
24 Q2-41.25M
24 Q1-40.86M
EBITDA (USD) · TTM
-40M-30M-20M-10M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
KALA EBITDA (USD) · TTM by quarter
PeriodEBITDA (USD) · TTM
26 Q2-8.79M
26 Q1-17.22M
25 Q4-23.39M
25 Q3-30.98M
25 Q2-31.92M
25 Q1-29.97M
24 Q4-32.47M
24 Q3-32.84M
24 Q2-32.52M
24 Q1-33.39M
Cash Flows (USD) · TTM
-40M-30M-20M-10M024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
KALA Cash Flows (USD) · TTM by quarter
PeriodCash Flows (USD) · TTM
26 Q2-19.86M
26 Q1-26.06M
25 Q4-31.99M
25 Q3-32.09M
25 Q2-25.9M
25 Q1-27.42M
24 Q4-29.45M
24 Q3-32.49M
24 Q2-31.04M
24 Q1-29.6M
EPS (USD) · TTM
-300-200-100024 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
KALA EPS (USD) · TTM by quarter
PeriodEPS (USD) · TTM
26 Q2-81.82
26 Q1-146
25 Q4-209.49
25 Q3-211.23
25 Q2-159.66
25 Q1-77.32
24 Q4-11.03
24 Q3-12.47
24 Q2-13.95
24 Q1-15.15
Expenses (USD) · TTM
020M40M60MR&DSG&ACapex24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
KALA Expenses (USD) · TTM by quarter
PeriodExpenses (USD) · TTM
26 Q224.36M
26 Q133.52M
25 Q442.37M
25 Q341.64M
25 Q240.45M
25 Q139.17M
24 Q440.24M
24 Q340.06M
24 Q241.24M
24 Q141.01M
Shares Outstanding (USD) · TTM
-10M-7.5M-5M-2.5M0Buybacks (Repurchases)Stock-Based Compensation24 Q124 Q224 Q324 Q425 Q125 Q225 Q325 Q426 Q126 Q2
KALA Shares Outstanding (USD) · TTM by quarter
PeriodShares Outstanding (USD) · TTM
26 Q2-1.97M
26 Q1-4.21M
25 Q4-7.01M
25 Q3-8.7M
25 Q2-8.69M
25 Q1-8.34M
24 Q4-8.39M
24 Q3-8.67M
24 Q2-9.04M
24 Q1-8.52M
Employee Count
050100150200201720182019202020212022202320242025
KALA Employee Count by quarter
PeriodEmployee Count
20256
202438
202343
202234
2021192
2020188
2019136
2018130
201737
Free Cash Flow Yield
-60000%-40000%-20000%0%med -105.65%Nov 24Mar 25Jun 25Oct 25Jan 26May 26Sep 26
KALA Free Cash Flow Yield by quarter
PeriodFree Cash Flow Yield
Sep 26-46793.05%
Sep 26-52797.84%
Aug 26-38812.26%
Aug 26-32659.85%
Aug 26-11607.42%
Aug 26-14676.14%
Jul 26-14518.87%
Jul 26-17304.97%
Jul 26-14146.45%
Jul 26-9300.69%
Jul 26-6532.63%
Jun 26-4355.08%
Jun 26-3040.11%
Jun 26-4172.93%
Jun 26-5327.58%
May 26-4921.44%
May 26-4516.38%
May 26-3745.67%
Apr 26-2244.38%
Apr 26-2676.9%
Mar 26-2594.58%
Mar 26-1924.02%
Mar 26-1627.17%
Mar 26-1638.88%
Feb 26-1198.97%
Feb 26-1198.97%
Feb 26-1120.53%
Feb 26-1035.47%
Jan 26-859.64%
Jan 26-753.07%
Jan 26-674.98%
Jan 26-721.36%
Jan 26-733.43%
Dec 25-700.94%
Dec 25-732.25%
Dec 25-674.78%
Dec 25-506.23%
Nov 25-471.55%
Nov 25-734.85%
Nov 25-563.12%
Nov 25-557.12%
Oct 25-509.84%
Oct 25-499.72%
Oct 25-303.57%
Oct 25-278.09%
Oct 25-258.23%
Sep 25-20.88%
Sep 25-20.26%
Sep 25-21.36%
Sep 25-27.33%
Aug 25-35.44%
Aug 25-43.18%
Aug 25-47.8%
Aug 25-53.89%
Aug 25-57.61%
Jul 25-53.41%
Jul 25-75.27%
Jul 25-73.86%
Jul 25-84.72%
Jun 25-93.52%
Jun 25-106.95%
Jun 25-100.48%
Jun 25-104.36%
May 25-116.15%
May 25-106.95%
May 25-117.73%
May 25-3.67%
May 25-3.35%
Apr 25-3.95%
Apr 25-3.63%
Apr 25-3.72%
Apr 25-2.96%
Mar 25-2.32%
Mar 25-2.03%
Mar 25-2.14%
Mar 25-1.99%
Feb 25-2.03%
Feb 25-2.11%
Feb 25-1.68%
Feb 25-1.27%
Jan 25-1.53%
Jan 25-1.73%
Jan 25-1.94%
Jan 25-2.06%
Jan 25-1.77%
Dec 24-2.01%
Dec 24-2.37%
Dec 24-2.27%
Dec 24-2.07%
Nov 24-2.05%
Nov 24-2.07%
Nov 24-2.1%
Nov 24-2.69%
Nov 24-2.93%
Oct 24-3.01%
Oct 24-3.94%
Oct 24-3.89%
Oct 24-3.79%
Sep 24-3.83%
Sep 24-3.54%
Price to Sales
010002000300040005000med 256.03Feb 22Jun 22Sep 22Dec 22Apr 23Jul 23Nov 23
KALA Price to Sales by quarter
PeriodPrice to Sales
Nov 231583.33
Nov 231989.83
Oct 231938.66
Oct 232092.16
Oct 232322.36
Oct 232518.5
Sep 232529.92
Sep 232940.51
Sep 233021.7
Sep 233146.77
Sep 233755.09
Aug 233865.95
Aug 233880.16
Aug 233826.15
Aug 234013.77
Jul 23608.44
Jul 23604.74
Jul 23592.43
Jul 23613.37
Jun 23599
Jun 23603.92
Jun 23593.25
Jun 23594.48
Jun 23678.23
May 23617.88
May 23681.11
May 23668.38
May 23299.28
Apr 23308.07
Apr 23307.68
Apr 23324.87
Apr 23269.58
Mar 23294
Mar 23304.16
Mar 23270.76
Mar 23368.24
Mar 23327.21
Feb 23149.95
Feb 23165.99
Feb 23192.07
Feb 23229.23
Jan 23256.22
Jan 23237.97
Jan 23255.83
Jan 23383.23
Dec 22497.45
Dec 2250.59
Dec 2255.03
Dec 2265.2
Dec 2265.46
Nov 2274.85
Nov 2280.45
Nov 2291.14
Nov 2246.11
Oct 2253.71
Oct 2270.21
Oct 22110.14
Oct 22118.48
Sep 2297.15
Sep 22110.93
Sep 22136.03
Sep 22149.85
Sep 22147.49
Aug 22128.48
Aug 22136.03
Aug 22147.49
Aug 22133.75
Jul 22130.01
Jul 22131.82
Jul 22133.91
Jul 22133.63
Jul 22117.32
Jun 22142.38
Jun 22154.71
Jun 22142.58
Jun 22149.71
May 22138.24
May 22254.7
May 22197.81
May 22226.64
Apr 22187.95
Apr 22216.74
Apr 22246.72
Apr 22298.05
Apr 22379.08
Mar 22514.94
Mar 22436.58
Mar 22472.96
Mar 22174.02
Feb 22190.08
Feb 22200.16
Feb 22199.51
Feb 22220.53
Jan 22220.78
Jan 22226.83
Jan 22291.05
Jan 22302.25
Dec 21338.63
Dec 21380.61
Dec 21391.8
Price to Book
0100200300400med 80.38Mar 24Jun 24Oct 24Jan 25May 25May 26Sep 26
KALA Price to Book by quarter
PeriodPrice to Book
Sep 260
Sep 260
Aug 260.01
Aug 260.01
Aug 260.02
Aug 260.02
Jul 260.02
Jul 260.01
Jul 260.02
Jul 260.03
Jul 260.04
Jun 260.06
Jun 260.08
Jun 260.06
Jun 260.05
May 260.05
May 260.05
May 260.06
Aug 258.34
Jul 258.99
Jul 256.38
Jul 256.5
Jul 255.67
Jun 255.14
Jun 254.49
Jun 254.78
Jun 254.6
May 254.14
May 254.49
May 254.08
May 2565.1
May 2571.38
Apr 2560.53
Apr 2565.76
Apr 2564.15
Apr 2580.71
Mar 25204.09
Mar 25233.44
Mar 25220.96
Mar 25237.82
Feb 25233.77
Feb 25223.99
Feb 25282.69
Feb 25371.74
Jan 25310.35
Jan 25273.58
Jan 25244.57
Jan 25229.73
Jan 25267.51
Dec 24235.46
Dec 24199.7
Dec 24208.47
Dec 24229.05
Nov 24231.33
Nov 24229.22
Nov 24226.02
Nov 2484.28
Nov 2477.21
Oct 2475.11
Oct 2457.44
Oct 2458.2
Oct 2459.65
Sep 2459.09
Sep 2463.95
Sep 2465.28
Sep 2466.27
Aug 2464.62
Aug 2466.38
Aug 2467.49
Aug 2464.62
Aug 24124.59
Jul 24145.81
Jul 24142.75
Jul 24157.96
Jul 24145.71
Jun 24149.72
Jun 24114.03
Jun 24125.86
Jun 24138.74
May 24141.91
May 24137.51
May 24138.32
May 24124.71
May 24126.65
Apr 24113.86
Apr 24119.1
Apr 24130.13
Apr 24137.36
Mar 2490.55
Mar 2490.78
Mar 2485.55
Mar 2485.21
Mar 2483.28
Feb 2480.21
Feb 2480.55
Feb 2483.73
Feb 2479.08
Jan 2480.89
Jan 2484.3
Jan 2491.46
KALA BIO, Inc.
KALA
Stockpicker

Video analysis: KALA

All videos

No video analysis for this stock yet. Request one from our team.

Your email is used only to follow up on this request. We do not add you to marketing lists. Privacy Policy

News: KALA

Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program

globenewswire.com · 3 Sep 2026

Kala Bio and Virotek Finalize Definitive Agreement Establishing Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program

Agreement Grants Kala Exclusive U.S. Rights to Market and Distribute Virotek's Ophthalmology Genomic Testing Program Agreement Grants Kala Exclusive U.S. Rights to Market and Distribute Virotek's Ophthalmology Genomic Testing Program

Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program

globenewswire.com · 1 Sep 2026

Kala Bio and Virotek Announce Letter of Intent to Establish an Exclusive U.S. Distribution Partnership for Ophthalmology Genetic Testing Program

ARLINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kala Bio, Inc. (Nasdaq: KALA) ("Kala") and Virotek Inc. ("Virotek"), a CLIA-registered precision health and clinical genomics company, today announced that they have entered into a letter of intent (the "LOI") outlining the principal terms under which the companies intend to negotiate a definitive agreement appointing Kala as the exclusive distributor and reseller in the United States of Virotek's genetic testing and screening program for ophthalmological indications.

KALA BIO (KALA) Expected to Post Earnings on Thursday

defenseworld.net · 30 Jul 2026

KALA BIO (KALA) Expected to Post Earnings on Thursday

KALA BIO (NASDAQ: KALA - Get Free Report) is anticipated to release its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect KALA BIO to post earnings of ($6.00) per share for the quarter. Parties can find conference call details on the company's upcoming Q2 2026 earning report for the latest details

Similar companies

Disclaimer: The historical data presented on this platform is provided by Financial Modeling Prep. Stock Picker is a platform for informational purposes only and does not provide financial advice. Users are encouraged to conduct their own research and consult with a qualified financial advisor before making investment decisions.